Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis.

× No keyword cloud information.

10 in total

Review 1. [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].

Authors: G Horneff
Journal: Z Rheumatol Date: 2010-08 Impact factor: 1.372

2. Spontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept.

Authors: Ariane Klein; Harald Reinhard; Annette M Mueller; Gerd Horneff
Journal: Eur J Rheumatol Date: 2017-02-23

3. [Comment of the Society of Pediatric and Adolescent Rheumatology on the US Food and Drug Administration (FDA) announcement regarding cases of malignancy in anti-TNF-treated patients].

Authors: T Hospach; J P Haas; H I Huppertz; R Keitzer; H Michels; R Trauzeddl; D Föll; G Dannecker; G Horneff
Journal: Z Rheumatol Date: 2009-03 Impact factor: 1.372

4. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

Authors: Hélène Théophile; Thierry Schaeverbeke; Ghada Miremont-Salamé; Abdelilah Abouelfath; Valentine Kahn; Françoise Haramburu; Bernard Bégaud
Journal: Drug Saf Date: 2011-07-01 Impact factor: 5.606

Review 5. The safety profile of biologic therapies for juvenile idiopathic arthritis.

Authors: Philip J Hashkes; Yosef Uziel; Ronald M Laxer
Journal: Nat Rev Rheumatol Date: 2010-08-31 Impact factor: 20.543

6. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.

Authors: Timothy Beukelman; Kevin Haynes; Jeffrey R Curtis; Fenglong Xie; Lang Chen; Christina J Bemrich-Stolz; Elizabeth Delzell; Kenneth G Saag; Daniel H Solomon; James D Lewis
Journal: Arthritis Rheum Date: 2012-02-10

7. Summary of worldwide pediatric malignancies reported after exposure to etanercept.

Authors: Peter McCroskery; Carol A Wallace; Daniel J Lovell; Scott Stryker; Nataliya Chernyukhin; Consuelo Blosch; Debra J Zack
Journal: Pediatr Rheumatol Online J Date: 2010-06-14 Impact factor: 3.054

Review 8. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.

Authors: Alex R Kemper; Heather A Van Mater; Remy R Coeytaux; John W Williams; Gillian D Sanders
Journal: BMC Pediatr Date: 2012-03-15 Impact factor: 2.125

9. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types.

Authors: Yuka Gion; Noriko Iwaki; Katsuyoshi Takata; Mai Takeuchi; Keiichiro Nishida; Yorihisa Orita; Tomoyasu Tachibana; Tadashi Yoshino; Yasuharu Sato
Journal: Cancer Sci Date: 2017-05-23 Impact factor: 6.716

10. Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study.

Authors: Alexandra Okihiro; Rachana Hasija; Lillia Fung; Bonnie Cameron; Brian M Feldman; Ronald Laxer; Rayfel Schneider; Earl Silverman; Lynn Spiegel; Rae S M Yeung; Shirley M L Tse
Journal: Pediatr Rheumatol Online J Date: 2018-03-14 Impact factor: 3.054

10 in total